Xuemei Liao

Dr. Xuemei Liao

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2024 in Chemical Society Reviews
Verified
Journal Article
Closed access
PDF file
MJMinghang Jiang
Minghang Jiang
HWHuaizhu Wang
Huaizhu Wang
MZMengfei Zhu
Mengfei Zhu
XLXiaojun Luo
Xiaojun Luo
YHYi He
Yi He
Zhong JinZhong Jin
Zhong Jin
This review summarizes promising strategies including the design of catalysts and the construction of coupled electrocatalytic reaction systems, aimed at achieving the selective production of various products from CO2 electroreduction.

22 November 2021 in Journal of Materials Chemistry A
Verified
Journal Article
Open access
PDF file
XZXiong Zhang
Xiong Zhang
LTLai Truong-Phuoc
Lai Truong-Phuoc
XLXuemei Liao
Xuemei Liao
VPVasiliki Papaefthimiou
Vasiliki Papaefthimiou
MPMatteo Pugliesi
Matteo Pugliesi
CPCuong Pham-Huu
Cuong Pham-Huu
A hierarchically porous N/C-network containing atomically dispersed Cl–FeN 4 nuclei as superior ORR electrocatalysts in an alkaline environment.

26 February 2020 in Cancer Science
Verified
Journal Article
Open access
PDF file
XLXuemei Liao
Xuemei Liao
YHYuan Hong
Yuan Hong
YMYu Mao
Yu Mao
NCNa Chen
Na Chen
QWQian Wang
Qian Wang
YLYanJun Liu
YanJun Liu
The cyclin‐dependent kinase (CDK)4/6‐cyclin D1‐Rb‐p16/ink4a pathway is responsible for regulating cell progression past the G1 restriction point during the cell cycle. The development of a majority of human tumors is associated with dysregulation of this pathway, resulting in increased cancer cell proliferation. Both CDK4 and CDK6, well‐validated cancer drug targets, function primarily as catalytic enzymes that mediate the phosphorylation of retinoblastoma protein (Rb). Here, we determined that SPH3643 is a novel potent antiproliferative agent that inhibits CDK4/6 kinase activity. In biochemical assays, SPH3643 showed more potent inhibition of both CDK4 and CDK6 than did 2 published CDK4/6 inhibitors, LY2835219 and palbociclib, and had better selectivity than LY2835219. Further in vitro study revealed that SPH3643 blocked Cdk/Rb signaling by inhibiting the phosphorylation of RbSer780 and arrested the MCF‐7 cancer cells at G0/G1 phase, resulting in marked inhibition of the proliferation of Rb‐positive cancer cell lines. In vivo SPH3643 treatment in mice bearing xenograft tumor models of breast cancer, colon cancer, acute myelocytic leukemia, and glioblastoma resulted in significant decreases in tumor growth. SPH3643 was able to particularly strongly inhibit glioblastoma (U87‐MG) cell growth in the brains of orthotopic carcinoma xenograft mice due to its high degree of intracerebral penetration and significant persistence in this setting. Together these results revealed that SPH3643 is a potent, orally active small‐molecule inhibitor of CDK4/6 with robust anticancer efficacy and a high degree of blood‐brain barrier permeability.

18 June 2024 in Journal of Hazardous Materials
Verified
Journal Article
Closed access
MJMinghang Jiang
Minghang Jiang
MZMengfei Zhu
Mengfei Zhu
JDJunjie Ding
Junjie Ding
HWHuaizhu Wang
Huaizhu Wang
QYQianchuan Yu
Qianchuan Yu
Zhong JinZhong Jin
Zhong Jin

16 October 2017 in RSC Advances
Verified
Journal Article
Open access
PDF file
JHJindou Hou
Jindou Hou
Wen LuoWen Luo
Wen Luo
SLShizhong Luo
Shizhong Luo
CLChao Lin
Chao Lin
PLPing Liu
Ping Liu
Xiaopeng LiXiaopeng Li
Xiaopeng Li
Synthesis of 2-methylpyrazine requires the well-designed CuMAl catalysts with bifunctional sites. Through alternating M species (M = Cr, Mn, Zn, and Co), highly dispersed Cu0 and high surface acidity can be achieved, thereby approaching the optimized catalytic performance.

12 May 2026 in Catalysts
Verified
Journal Article
Open access
PDF file
HLHao Luo
Hao Luo
QDQiao Dai
Qiao Dai
TMTing Mo
Ting Mo
YWYunye Wang
Yunye Wang
CLChenghao Lei
Chenghao Lei
XLXuemei Liao
Xuemei Liao
This study presents an approach for the “one-pot two-step” synthesis of 2,5-diformylfuran (DFF) from fructose using a metal-free phosphorus-doped carbon nitride (P-CN) catalyst. The bifunctional P-CN integrates P-O bonds for acid-catalyzed fructose dehydration to 5-hydroxymethylfurfural (HMF) and P-C/graphitic-N sites for selective aerobic HMF oxidation to DFF. The 10% P-CN catalyst achieved 91.5% DFF yield during the stepwise oxidation of isolated HMF under the mild conditions (1.5 MPa O2, 120 °C), while the “one-pot” cascade reaction yielded 63% DFF due to competing side reactions. Characterization revealed that P-doping enhanced porosity (883 m2/g surface area) and electronic properties, with graphitic-N facilitating O2 activation. P=O groups are hypothesized to mediate proton transfer from reactive substrates via hydrogen-bonding networks, thereby enhancing acid-catalyzed pathways. NH3-TPD and XPS confirmed tailored acid sites and P-N/C elemental synergism, while FT-IR demonstrated substrate adsorption via P=O/HMF-OH interactions. The catalyst retained stability over multiple cycles, demonstrating its practicality. This work advances biomass valorization by elucidating the dual-role design of nonmetallic catalysts, offering an eco-friendly alternative to conventional metal-based systems.